report publish origin email
robust outlook pt rais
thesi reiter buy edward follow robust result
rais adjust ep reflect benefit us tax reform
rais transcathet valv therapi thvt revenu gross margin
estim posit currenc effect rais price target
three-year target
estim adjust ep growth
extent mark transit year next materi catalyst expect
public clinic trial support regulatori approv
tavr use low-risk asymptomat patient expand market howev
still expect revenu growth adjust ep growth transit
year robust perform across busi area given edward strong
momentum
strong pipelin expect posit increment updat year
addit edward develop strong suit mitral tricuspid valv repair
replac devic highlight report follow capit
market day decemb transit year long term outlook robust
expect seri potenti posit data point around studi highlight
potenti devic compani new tavr devic sapien ultra
edward remain best place benefit long-term structur growth
opportun offer transcathet valv replac remind expect
transcathet aortic valv replac tavr market edward market
leader tripl addit edward given initi guidanc
transcathet mitral tricuspid valv repair replac market reach
robust ahead guidanc
edward lifesci report strong sale yoy
underli ahead bloomberg consensu support strong end
import note inform cover standard regulatori disclosur
print publish research display www redburn com
redburn europ limit authoris regul financi conduct author
year thvt posit currenc effect adjust net incom grew yoy
adjust ep grew ahead consensu net incom
million per share one-tim tax charg net
relat primarili repatri unremit foreign earn
thvt sale grew underli million sequenti acceler
ahead manag guidanc given decemb double-digit growth
across region stronger expect finish help none
typic season fall-off decemb procedur volum strong end
year result also benefit robust adopt lower volum market
compani ad new centr offer tavr total call
manag admit slightli ahead initi expect
howev surgic heart valv therapi shvt sale also beat expect
underli growth driven share gain driven new product
inspiri critic sale growth underli also encourag
ahead market growth particularli strong demand us china
strong sale perform improv mix higher tavr sale support
edward gave initi guidanc recent decemb capit market day
strong tavr revenu momentum result compani
guid underli revenu growth thvt upper end
growth rang revenu growth guidanc shvt critic
unchang addit support usd weak edward see
group sale higher end guidanc
follow tax reform manag confirm expect group effect rate
 assum adjust ep guidanc rais
rang previous
transit year underli sale growth still
although expect catalyst us eu approv low-risk asymptomat
patient expect still expect group organ growth
organ growth edward transcathet valv therapi tvr
revenu forecast market still grow
expect tavr market compound-annual-growth-rate support expand penetr
amongst intermedi risk patient us europ increas market penetr
asia particularli japan uptak low-risk patient
growth outlook ahead sector
estim adjust ep compound-annual-growth-rate one highest
larg cap medic technolog sector expect earn growth acceler
sustain mid-teen earn growth
support low-risk approv us europ like support increas
utilis tavr asymptomat patient launch edward suit
import note inform cover standard regulatori disclosur
print publish research display www redburn com
redburn europ limit authoris regul financi conduct author
mitral tricuspid valv repair product uptak transcathet
note edward face toughest compar quarterli perform
underli revenu growth adjust stock thu
see sequenti acceler revenu earn growth year
price target rais three-year target
rais price target reflect benefit us
tax reform rais margin assumpt higher currenc benefit form usd
weak
assum edward justifi premium broader us sector reflect
sector-lead organ growth potenti materi improv
profit return capit leverag histor invest assum
ew justifi premium sector ten-year averag rel premium
reflect slowdown revenu growth tavr market matur
gradual loss market share competit increas well lower mid-term
earn growth outlook achiev histor smaller compani
assum us med-tech justifi small premium wider market
ten-year averag premium current stage wider econom
cycl potenti rise rate inflat expect sector trade
discount histor rel valuat
edward trade price-to-earnings premium sector
sector rel valuat offer support mid-term
outlook edward robust rais three-year target
import note inform cover standard regulatori disclosur
print publish research display www redburn com
redburn europ limit authoris regul financi conduct author
fig chang forecast
import note inform cover standard regulatori disclosur
print publish research display www redburn com
redburn europ limit authoris regul financi conduct author
import note inform cover standard regulatori disclosur
